Poslední aktualizace :
29/10/2024
rakovina drog   Dacarbazine  
injekce
Stabilita roztoků Stabilita směsí Faktory ovlivňující stabilitu Kompatibilita Způsoby aplikace Odkazy pdf
   Chemický vzorec  

Obchodní název   Obchodní název     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Acocarb Mexiko
Celdaz Indie, Peru
Dabaz Indie
Dacarb Indie, Peru
Dacarba Indie
Dacarbaz Turecko
Dacarbazin Malajsie, MaÔarsko, Polsko, Rakousko
Dacarbazina äpanÏlsko, Argentina, Chile, Ekvádor, Kolumbie
Dacarbazine Austrálie, Belgie, Dánsko, Indie, Írán, Irsko, Kanada, nový Zéland, Švédsko, USA, Velká Británie
Dacarex Indie, Peru
Dacarin Indie
Dacarpalm Peru
Dacarzine Indie
Dacatic Finsko
Dacin Švýcarsko
Dacmed Indie
Daracina Kolumbie
Deticene Francie, Itálie, Nizozemsko, Saúdská Arábie, Tunisko, ÿecko
Detilem Mexiko
Detimedac Kolumbie, NÏmecko
DTI Malajsie
DTIC Austrálie, nový Zéland, Rakousko, Švédsko, USA, Velká Británie
Fauldetic Portugalsko
Ifadac Mexiko
Oncocarbil Argentina, Ekvádor, Peru
Tiferomed Mexiko
Odkazy   injekce   Odkazy : Dacarbazine  
typ uveřejnění
3 noviny Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26 noviny Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
40 noviny Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC.
Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags.
Pharm Sci Communications 1994 ; 4: 97-101.
57 noviny Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 noviny Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 noviny Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 noviny Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 noviny Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
184 noviny Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 noviny Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 noviny Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 noviny Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 noviny Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 noviny Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 noviny Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 noviny Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
353 noviny Lunn G, Sansone EB.
Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid.
Am J Hosp Pharm 1987 ; 44: 2519-2524.
492 noviny Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
860 noviny Nelson RW, Young R, Lamnin M.
Visual incompatibility of dacarbazine and heparin.
Am J Hosp Pharm 1987 ; 44: 2028.
905 noviny Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1383 noviny Stevens MFG, Peatey L.
Photodegradation of solutions of the antitumour drug DTIC.
J Pharm Pharmacol 1978 ; 30: 47P.
1410 noviny Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1501 noviny Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1635 noviny El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F.
Stability of dacarbazine in amber glass vials and polyvinyl chloride bags.
Am J Health-Syst Pharm 2002 ; 59: 1351-1356.
2107 noviny Trissel LA, Zhang Y, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Int J Pharm Compound 2006 ; 10: 234-236.
3266 Laboratoř Lipomed Laboratories
Dacarbazine solutions: In Use stability of dacarbazine lipomed®
Lipomed 2011
3267 Laboratoř Lipomed Laboratories
Dacarbazine Lipomed - Summary of Product Characteristics
Lipomed 2011
3540 Laboratoř Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3605 Laboratoř Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit
Lipomed 2010

  Mentions Légales